FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease
Share
Tweet
The U.S. Food and Drug Administration approved Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), to be used along with diet and exercise.
“Pr...
For access to this article please
sign in or
subscribe.
Reader Comments(0)